With rising demand and the complexities of manufacturing oligo-based therapies, contract developers and manufacturers stand to benefit from the sector’s expansion.
Three facilities passed a five-day inspection with zero findings, enabling end-to-end commercial manufacturing of anti-PD-L1 monoclonal antibody for Brazilian market.
Go beyond similarity in this webchat with a Thermo Fisher Scientific expert on how a p-value-based multivariate residual approach verifies pharmaceutical raw materials.
UV is a comprehensive solution for chloramine reduction and can work synergistically with activated carbon, helping to reduce waste, lower operating costs, and minimize the amount of carbon needed over time.
